-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Zolitinib is a next-generation EGFR-TKI drug designed for the treatment of advanced non-small cell lung cancer with CNS metastases, with the ability to completely penetrate the blood-brain barrier Top-level data from this clinical study are expected to be generated by the end of 2022
SHANGHAI, Aug.
As the principal investigator of the EVEREST clinical trial, Professor Wu Yilong, chairman of the China Thoracic Oncology Research Collaborative Group (CTONG), said: "The EVEREST study is a randomized, open-label, international multi-center Phase II/III clinical study.
As the co-principal investigator of the EVEREST clinical trial, Professor Wang Jie, director of the Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, said: "Lung cancer with central nervous system metastasis has always been a clinical problem to be solved, and it is also the main cause of death for those patients
In addition, Song Ruilin, executive chairman of the China Pharmaceutical Innovation Promotion Association, also said: "In the past three years, the new crown pneumonia epidemic in some parts of the country has brought great challenges to innovative pharmaceutical companies.
About Zolitinib
Zolitinib is a potent, oral, reversible epidermal growth factor receptor activating mutant (L858R and Exon 19Del) tyrosine kinase activity inhibitor (EGFR-TKI)
Source: Chentai Pharmaceuticals
